Treatment | Collection Time | Percentage of the Urinary Radioactivity | ||||
---|---|---|---|---|---|---|
Fraction 15-a | EPE | Fraction 25-a | GA1 | GA2 | ||
Without hydrolysis | 0–24 h | 6.5 ± 0.4 | 1.6 | 81.6 ± 1.1 | 20 | 37 |
24–48 h | 6.9 ± 1.6 | 1.8 | 80.1 ± 1.6 | 15 | 41 | |
β-glucuronidase | 0–24 h | 68.7 ± 1.1 | 58.7 | 15.9 ± 0.6 | 0.4 | 0.6 |
(E. coli) | 24–48 h | 68.9 ± 1.4 | 60.1 | 15.1 ± 1.5 | 0.2 | <0.1 |
β-glucuronidase | 0–24 h | 37.2 ± 0.9 | 31.6 | 46.9 ± 0.6 | 0.7 | 27 |
(H. pomatia) | 24–48 h | 30.1 ± 1.1 | 26.4 | 54.1 ± 0.9 | 0.9 | 35 |
Urine from rats, dosed orally with 100 mg/kg [14C]1,2-DEB, was collected on a 0- to 24- and 24- to 48-h period. Aliquots of each urine were incubated with β-glucuronidase from E. coli orH. pomatia. The neutral (fraction 1) and acidic (fraction 2) metabolites were separated as described in Materials and Methods. The radioactivity content was measured on an aliquot of each fraction. Then aliquots of each fraction from the same treatment were pooled and EPE, GA1, and GA2 metabolites of [14C]1,2-DEB were quantified by HPLC.
↵5-a Data expressed as mean ± S.E. (n= 5).